Have a personal or library account? Click to login
β-Elemene inhibits the proliferation and migration of human glioblastoma cell lines via suppressing ring finger protein 135 Cover

β-Elemene inhibits the proliferation and migration of human glioblastoma cell lines via suppressing ring finger protein 135

Balkan Journal of Medical Genetics
Volume 23 (2020): Issue 1 (June 2020)
By: M Alizada,  J Li,  H Aslami,  D Yang,  T Korchuganova and  YH Xu  
Open Access
|Aug 2020

Figures & Tables

Figure 1

The expression level of RNF135 is suppressed in human glioblastoma cell lines U251, U118, U87 and A172 treated with β-elemene. The data from qRT-PCR (Author: see Abstract) of three independent experimental groups showed that the cell lines treated with β-elemene have a lower level of RNF 135 mRNA than the control group (p <0.05) (A-D). The data from Western blot also confirmed that protein levels of RNF135 were lower in the cell lines that were treated with β-elemene than those of the control group (E-H). Glyceraldehyde 3-phosphate dehydrogenase was used for both qRT-PCR and Western blot as loading control.
The expression level of RNF135 is suppressed in human glioblastoma cell lines U251, U118, U87 and A172 treated with β-elemene. The data from qRT-PCR (Author: see Abstract) of three independent experimental groups showed that the cell lines treated with β-elemene have a lower level of RNF 135 mRNA than the control group (p <0.05) (A-D). The data from Western blot also confirmed that protein levels of RNF135 were lower in the cell lines that were treated with β-elemene than those of the control group (E-H). Glyceraldehyde 3-phosphate dehydrogenase was used for both qRT-PCR and Western blot as loading control.

Figure 2

Increasing β-elemene treatment dose decreases viability of glioblastoma cells. Human glioblastoma cell lines U251, U118, U87 and A172 were sown at the concentration of 5000 cells per well in 96-well plates and treated with various doses (0, 20, 40, 60, 80 and 100 μg/mL) of β-elemene. The half maximal inhibitory effects (IC50) of the cells were obtained by doses of 47.44, 49.68, 58.41 and 57.36 μg/mL of β-elemene, respectively (A-D). The CCK-8 was utilized to ascertain cell viability and inhibitory effect of β-elemene on the proliferation of the cells. The results are shown as mean ± SD of the three experiments (p <0.05, the difference is statistically significant in the untreated control group).
Increasing β-elemene treatment dose decreases viability of glioblastoma cells. Human glioblastoma cell lines U251, U118, U87 and A172 were sown at the concentration of 5000 cells per well in 96-well plates and treated with various doses (0, 20, 40, 60, 80 and 100 μg/mL) of β-elemene. The half maximal inhibitory effects (IC50) of the cells were obtained by doses of 47.44, 49.68, 58.41 and 57.36 μg/mL of β-elemene, respectively (A-D). The CCK-8 was utilized to ascertain cell viability and inhibitory effect of β-elemene on the proliferation of the cells. The results are shown as mean ± SD of the three experiments (p <0.05, the difference is statistically significant in the untreated control group).

Figure 3

Increasing the time of treatment with β-elemene decreases glioblastoma cells viability. The 5000 cells per well were sown in 96-well plates. Cell lines U251 and U118 were treated with 50 μg/mL β-elemene and cell lines U87 and A172 were treated with 60 μg/ mL β-elemene for 0, 24, 48, 72, 96, 120 and 144 hours (A-D). The CCK-8 was utilized to determine inhibitory effect of β-elemene on the proliferation of the cells in different time intervals. The results are shown as mean ± SD of the three experiments (p <0.05, the difference is statistically significant in the untreated control group).
Increasing the time of treatment with β-elemene decreases glioblastoma cells viability. The 5000 cells per well were sown in 96-well plates. Cell lines U251 and U118 were treated with 50 μg/mL β-elemene and cell lines U87 and A172 were treated with 60 μg/ mL β-elemene for 0, 24, 48, 72, 96, 120 and 144 hours (A-D). The CCK-8 was utilized to determine inhibitory effect of β-elemene on the proliferation of the cells in different time intervals. The results are shown as mean ± SD of the three experiments (p <0.05, the difference is statistically significant in the untreated control group).

Figure 4

Migration of human glioblastoma cell lines U251, U118, A172 and U87 were inhibited by β-elemene. In this wound healing assay, 5000 cells/well were sown into 6-well plates, cultured and photographed at the time intervals of 12, 24, 36 and 48 hours in at least three independent groups (β-elemene treated vs. control groups). The data were analyzed as mean ± SD and p <0.05. The human glioblastoma cells treated with β-elemene was found to have much lower speed moving to the gaps compared to the untreated control group cells (A-D).
Migration of human glioblastoma cell lines U251, U118, A172 and U87 were inhibited by β-elemene. In this wound healing assay, 5000 cells/well were sown into 6-well plates, cultured and photographed at the time intervals of 12, 24, 36 and 48 hours in at least three independent groups (β-elemene treated vs. control groups). The data were analyzed as mean ± SD and p <0.05. The human glioblastoma cells treated with β-elemene was found to have much lower speed moving to the gaps compared to the untreated control group cells (A-D).

Figure 5

β-Elemene suppresses U251 cell tumorigenicity in vivo. Five- to six-week old female nude mice were injected subcutaneously with (1 × 107) U251 cells and the tumor weights from the β-elemene-treated group and control group (untreated group) were measured at 28 days post-injection (A).The tumorigenicity of the U251 cells was remarkably reduced in the group that was treated with β-elemene as compared to the group that was not treated with β-elemene (p <0.05) (B). Immunohistochemistry staining of RNF135 of the tumors treated with β-elemene and not treated with β-elemene (control group), original magnification ×400, ×100 (C).
β-Elemene suppresses U251 cell tumorigenicity in vivo. Five- to six-week old female nude mice were injected subcutaneously with (1 × 107) U251 cells and the tumor weights from the β-elemene-treated group and control group (untreated group) were measured at 28 days post-injection (A).The tumorigenicity of the U251 cells was remarkably reduced in the group that was treated with β-elemene as compared to the group that was not treated with β-elemene (p <0.05) (B). Immunohistochemistry staining of RNF135 of the tumors treated with β-elemene and not treated with β-elemene (control group), original magnification ×400, ×100 (C).
DOI: https://doi.org/10.2478/bjmg-2020-0002 | Journal eISSN: 2199-5761
Journal RSS Feed
Language: English
Page range: 43 - 49
Published on: Aug 26, 2020
Published by: Macedonian Academy of Sciences and Arts
In partnership with: Paradigm Publishing Services
Publication frequency: 2 issues per year
Keywords:
β-Elemene,
Glioblastoma,
Migration,
Proliferation,
Ring finger protein 135 (RNF135),
Tumorigenicity
Related subjects:
Medicine,
Basic medical science,
Basic medical science, other

© 2020 M Alizada, J Li, H Aslami, D Yang, T Korchuganova, YH Xu, published by Macedonian Academy of Sciences and Arts
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Previous articleVolume 23 (2020): Issue 1 (June 2020)Next article